Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: A three-year study

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 4, 2007, Pages 351-358

  Gupta, Viney ^a   Srinivasan, Geetha ^a   Sharma, Ajay ^a   Kapoor, Kulwant S ^b   Sihota, Ramanjit ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; LIPID;

ADULT; ARTICLE; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; TREATMENT RESPONSE; AGED; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PROSPECTIVE STUDY; TIME; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; CLOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, ANGLE-CLOSURE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 35848929280     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0107     Document Type: Article

References (32)

1. Woodward, D.F., Krauss, A.H.P., Chen, J., et al. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 45:S337-S345, 2001.
2. Brandt, J., Vandenburgh, A.M., Chen, K., et al., for the Bimatoprost Study Group. Comparison of once- or twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 108:1023-1031, 2001.
3. Noecker, R.S., Dirks, M.S., Choplin, N.T., for the Bimatoprost/ Latanoprost Study Group. A six-month randomized, clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:55-63, 2003.
4. Simmons, S.T., Dirks, M.S., and Noecker, R.J. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: Results from parallel-group comparison trials. Adv. Ther. 21(4):247-262, 2004.
5. Cantor, L.B., Hoop, J., Morgan, L., et al., for the Bimatoprost- Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br. J. Ophthalmol. 90:1370-1373, 2006.
6. Cohen, J.S., Gross, R.L., Cheetham, J.K., et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. 49(Suppl 1):S45-S52., 2004.
7. Agarwal, H.C., Gupta, V., and Sihota, R. Effect of change over from timolol pilocarpine combination to bimatoprost monotherapy on ocular blood flow and intraocular pressure in primary chronic angle closure glaucoma. J. Ocul. Pharmacol. Ther. 19(2): 105-112, 2003.
8. Dirks, M.S., Noecker, R.J., Earl, M., et al. A 3-month clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with normal tension glaucoma. Adv. Therap. 23;385-394, 2006.
9. Orzalesi, N., Rosetti, L., Bottoli, A., et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthamol. 113(2):239-246, 2006.
10. Quigley, H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:389-393, 1996.
11. Thylefors, B., Negrel, A.D., PararajaSegaram, R., et al. Global data on blindness. Bull. World Health Org. 73:115-121, 1995.
12. Hodapp, E., Parrish, R.K., and Anderson, D.R. Clin. Decisions in Glaucoma. St Louis, MO: CV Mosby, 1993: 52-61.
13. Toris, C.B., Zhan, G.L., Zhao, J., et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am. J. Ophthalmol. 131:722-728, 2001.
14. Gabelt, B.T.,and Kaufman, P.L. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
15. Ziai, N., Dolan, J.W., Kacere, R.D., et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993.
16. Camras, C.B., Siebold, E.C., Lustgarten, J.S., et al. Maintained reduction of intraocular pressure by prostaglandin F2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 96:1329-1337, 1989.
17. Brubaker, R.F. Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol. 45(Suppl. 4):S347-S351, 2001.
18. Christiansen, G.A., Nau, C.B., McLaren, J.W., et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111:1658-1662, 2004.
19. Bayer, A., Weiler, W., Oeverhaus, U., et al., for the Xplore Observation Group. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. 20:470-478, 2004.
20. Mahdavi, K.N., Hoffman, D., Coleman, A.L., et al. Predictive factors for glaucomatous visual field progression. Ophthalmology 111:1627-1635, 2004.
21. Boger, W.P., III. Short-term escape and long-term drift: The dissipation effect of the beta-adrenergic blocking agents. Surv. Ophthalmol. 28:235-242, 1983.
22. Robin, A.L. The role of alpha agonists in glaucoma therapy. Curr. Opin. Ophthalmol. 10:1921-1925, 1997.
23. Chung, H.S., Shin, D.H., Birt, C.M., et al. Chronic use of apraclonidine decreases its moderation of post-laser spikes. Ophthalmology 10:1921-1925, 1997.
24. Bietsch, B.R., and Eakins, K.E. The effects of prostaglandins on the intraocular pressure of the rabbit. Br. J. Pharmacol. 37:158-160, 1969.
25. Eakins, K.E. Increased intraocular pressure produced by prostaglandin E1 and E2 in the cat eye. Exp. Eye Res. 10:87-89, 1970.
26. Bito, L.Z, Draga, A., Blanco, J., et al. Long-term maintenance of reduced intraocular pressure by daily or twice-daily topical application of prostaglandins to cat or rhesus monkey eyes. Inv. Ophthalmol. Vis. Sci. 24(3):312-319, 1983.
27. Kook, M.S., Cho, H.S., Yang, S.J., et al. Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: A preliminary study. J. Ocul. Pharmacol. Ther. 21(1):75-84, 2005.
28. Aung, T., Chan, Y.H., Chew, P.T. for the EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle closure glaucoma. Ophthalmology 112(2):267-271, 2005.
29. Sihota, R., Lakshmaiah, N.C., Walia, K.B. et al. The trabecular meshwork in acute and chronic angle closure glaucoma. Ind. J. Ophthalmol. 49(4):255-259, 2001.
30. Watson, P.G. Latanoprost: Two years of its use in the United Kingdom. The Latanoprost study group. Ophthalmology 105:82-87, 1998.
31. Costagliola, C., Del Prete, A.D., Verolino, M., et al. Effect of 0.005% latanoprost once-daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice-daily: A 3-year follow-up. Graefe's Arch. Clin. Exp. Ophthalmol. 240:379-386, 2002.
32. Higginbotham, E.J., Schuman, J.S., Goldberg, I., for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension Arch. Ophthalmol. 120:1286-1293, 2002.